Highlights from the SWG
The following activities, which were organized by EMN, also constitute contributions to and participation in the work of the EHA SWG on Multiple Myeloma.
Annual meetings
The SWG organized a session at the 24th Annual Meeting of EHA in Frankfurt entitled ‘Multiple Myeloma: Novel outcome endpoints in trials and in daily clinical practice.’
Also, a combined session of EHA and the International Myeloma Society (IMS) was organized at the Annual Meeting of the IMS in Athens. This session was entitled ‘Minimal Residual Disease in Multiple Myeloma.’
Active trials
EMN members perform collaborative research based on primary samples from patients participating in their clinical trials.
In 2023, EMN received a grant of $7 million from the Multiple Myeloma Research Foundation (MMRF) for molecular analysis of treatment resistance in high-risk disease.
During that year, members of the EHA SWG on Multiple Myeloma had a leading role in the following EMN trials.
EMN14
| Other identifying number/names |
54767414MMY3013 APOLLO |
| Setting |
RRMM |
| Study phase |
III |
| Drug(s) |
Dara Pd vs Pd |
| Principal investigator |
Professor E.Terpos |
| Countries (sites) |
Bel (4), Cze (2), Den (2), Fr (6), Ger (5), Gr (5), Ita (6), Ned (4), Pol (2), Ser (1), Spa (7), Tur (7) |
| Patients enrolled |
353 patients screened & 304 patients randomized |
| Number of patients needed |
302 randomized |
| Study milestones |
Final analysis summer 2022 (July 2020 was IA). Now in final follow up stage. Published |
EMN17
| Other identifying number/names |
MMY3014 - PERSEUS |
| Setting |
NDMM |
| Study phase |
III |
| Drug(s) |
Dara-VRd vs VRd |
| Principal investigator |
Prof. P. Sonneveld |
| Countries (sites) |
AU (6), BE (3), CZ (2), DN (7), FR (25), DE (3), GR (4), IT (29), NL (10), NO (2), PL (3), ES (21), SW (6), TR (5) |
| Patients enrolled |
709 |
| Number of patients needed |
690 (recruitment completed) Published 2023 |
EMN18
| Other identifying number/names |
None |
| Setting |
NDMM |
| Study phase |
II |
| Drug(s) |
Dara VCD vs VTD |
| Principal investigator |
Professors M.Boccadoro, M.Cavo |
| Countries (sites) |
CZ (6), GR (3), IT (19) |
| Patients enrolled |
401 |
| Number of patients needed |
400 (recruitment completed) |
EMN19
| Other identifying number/names |
ANTARES |
| Setting |
MM & extramedullary disease |
| Study phase |
II |
| Drug(s) |
Dara- CyBorD |
| Principal investigator |
Professor M. Beksac |
| Countries (sites) |
Gr (2) Ita (2) Tur (4) |
| Patients enrolled |
41 Recruitment completed |
| Number of patients needed |
40 |
EMN22
| Other identifying number/names |
54767414AMY2005 Alcaeus |
| Setting |
High Risk Amyloidosis |
| Study phase |
II |
| Drug(s) |
Dara |
| Principal investigator |
Professor S. Kastritis |
| Countries (sites) |
Gr (1), Ita (1), Ned (1), Fr (2) |
| Patients enrolled |
40 recruitment complete |
| Number of patients needed |
40 Completed, presented at ASH2023 |
EMN23
| Other identifying number/names |
54767414AMY0001 |
| Setting |
RWE Amyloidosis |
| Study phase |
Retrospective data collection |
| Drug(s) |
|
| Principal investigator |
Professor S.Kastritis |
| Countries (sites) |
Austria (1), Cze (1), Fr (2), Ger (1), Gr (1), Ita (1), Ned (2), Port (2), Sp (1), UK (1) |
| Patients enrolled |
Recruitment complete (4480 patients) |
| Number of patients needed |
Approx. 5000 (1st line AL-Amyloidosis patients treated from 2004 – 2018 incl.) |
EMN24
| Other identifying number/names |
ISKIA |
| Setting |
NDMM ASCT-eligible |
| Study phase |
III |
| Drug(s) |
Isa-KRd vs KRd |
| Principal investigator |
Professors F.Gay & A. Broijl |
| Countries (sites) |
BE (1), CZ (4), DE (3), ES (6), GR (2), IT (12), NL (13), NO (2) |
| Patients enrolled |
302 |
| Number of patients needed |
300 (recruitment completed) Presented at ASH2023 |
EMN26
| Other identifying number/names |
-- |
| Setting |
NDMM - maintenance post ASCT |
| Study phase |
II |
| Drug(s) |
Iberdomide |
| Principal investigator |
Professors F. Gay & vN. an de Donk |
| Countries (sites) |
FR (7), GR (2), IT (10), NL (7) |
| Patients enrolled |
88 |
| Number of patients needed |
120 (completed), presented at ASH2023 |
EMN27
| Other identifying number/names |
-- |
| Setting |
relapsed or refractory AL amyloidosis |
| Study phase |
II |
| Drug(s) |
Belantamab Mafodotin |
| Principal investigator |
Prof. Kastritis |
| Countries (sites) |
GR (1) IT (1) NL (1) FR (1) DE (1) UK (1) |
| Patients enrolled |
31 |
| Number of patients needed |
36 |
EMN28
| Other identifying number/names |
Cartitude-6 / Emagine study |
| Setting |
NDMM |
| Study phase |
III |
| Drug(s) |
DVRd+ASCT+DVRd+R vs DVRd+Cilta-cel+R |
| Principal investigator |
P. Sonneveld & M. Boccadoro |
| Countries (sites) |
AU, BE, CA, CZ, DE, FR, GR, IL, IT, JP, KR, NL, NO, ES, SE, CH, UK, USA |
| Patients enrolled |
100 – 105 |
| Number of patients needed |
750 pts. Ongoing |
EMN29
| Other identifying number/names |
- |
| Setting |
RRMM |
| Study phase |
III |
| Drug(s) |
Sel-Pom-dex vs Elo-Pom-dex |
| Principal investigator |
K. Weisel |
| Countries (sites) |
DE, FR, GR, NL, IT, ES, US |
| Patients enrolled |
22, 7 SF |
| Number of patients needed |
222 (per new Amendment) Ongoing |
EMN30
| Other identifying number/names |
MajesTEC-4 |
| Setting |
NDMM |
| Study phase |
III |
| Drug(s) |
Teclistamab – Lenalidomide maintenance post ASCT |
| Principal investigator |
E. Zamagni, N. Van de Donk |
| Countries (sites) |
16(115 sites) increasing to 24 (approx. 250 sites) |
| Patients enrolled |
32 patients |
| Number of patients needed |
1520 with amendment Ongoing |
EMN33
| Other identifying number/names |
Taurus |
| Setting |
NDMM |
| Study phase |
II |
| Drug(s) |
Dara-VRD MRD technique comparison |
| Principal investigator |
E. Zamagni, N. Van de Donk |
| Countries (sites) |
AT (4), DE (3), GR (3), IT (15), NL(8) |
| Patients enrolled |
Not enrolling yet |
| Number of patients needed |
200 |
EMN34
| Other identifying number/names |
- |
| Setting |
High-risk SMM |
| Study phase |
II |
| Drug(s) |
Elranatamab vs Rd |
| Principal investigator |
C. Touzeau & A. Broijl |
| Countries (sites) |
IT, NL, FR, GR |
| Patients enrolled |
Not enrolling yet |
| Number of patients needed |
50 Open for inclusion |
EMN Biobanking
| Other identifying number/names |
- |
| Setting |
MGUS, SMM, MM, PCL, EMD |
| Study phase |
observational |
| Drug(s) |
- |
| Principal investigator |
Dr. M van Duin, Dr. M D’Agostino |
| Countries (sites) |
IT (22), CZ (8), GR (2), AT (7), TR (3), RS (4) |
| Patients enrolled |
7 |
| Number of patients needed |
6000 |
EMN Covid data collection
| Other identifying number/names |
- |
| Setting |
Any MM patients with Covid-19 infection |
| Study phase |
observational |
| Drug(s) |
- |
| Principal investigator |
Prof. G. Cook |
| Countries (sites) |
IT (42), CZ (3), GR (3), BE (26), NL (4), AT (2), UK (6) |
| Patients enrolled |
1041 |
| Number of patients needed |
1000 |
Back